Zen Pharma Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 06-07-2024
- Paid Up Capital ₹ 2.14 M
as on 06-07-2024
- Company Age 29 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 26.06%
(FY 2022)
- Profit 0.93%
(FY 2022)
- Ebitda -10.93%
(FY 2022)
- Net Worth 10.27%
(FY 2022)
- Total Assets 15.65%
(FY 2022)
About Zen Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.14 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Gupta and Amit Gupta serve as directors at the Company.
- CIN/LLPIN
U24239MH1995PTC089178
- Company No.
089178
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jun 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Zen Pharma Private Limited offer?
Zen Pharma Private Limited offers a wide range of products and services, including Infusion Syringes & Supplies, Syringes.
Who are the key members and board of directors at Zen Pharma?
Board Members(2)
Financial Performance and Corporate Structure Insights of Zen Pharma.
Zen Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 26.06% increase. The company also saw a slight improvement in profitability, with a 0.93% increase in profit. The company's net worth Soared by an impressive increase of 10.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zen Pharma?
In 2021, Zen Pharma had a promoter holding of 34.36% and a public holding of 65.64%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sng Pharmaceuticals Private Limited
Active
21 years 5 months Anil Gupta and Amit Gupta are mutual person
Gujarat Ampoules And Vials Pvt Ltd
Active 36 years 11 months Anil Gupta and Amit Gupta are mutual person
Adit Containers Private Limited
Active 40 years 11 months Anil Gupta and Amit Gupta are mutual person
Adit Leasing And Finance Pvt Ltd
Active 37 years 4 months Anil Gupta and Amit Gupta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zen Pharma?
Zen Pharma has a workforce of 72 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zen Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zen Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
